相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
Maysa M. Abu-Khalaf et al.
NPJ PRECISION ONCOLOGY (2023)
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
N. Harbeck et al.
ANNALS OF ONCOLOGY (2021)
Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal Treatment and CDK 4/6 Inhibitors or Everolimus
Christos Papageorgiou et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice
Sushmita Rath et al.
PLOS ONE (2021)
Side effects of CDK4/6 inhibitors in the treatment of HR+/HER2-advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials
Lin Yang et al.
ANNALS OF PALLIATIVE MEDICINE (2021)
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2 A Randomized Clinical Trial
George W. Sledge et al.
JAMA ONCOLOGY (2020)
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
G. Curigliano et al.
ANNALS OF ONCOLOGY (2020)
Overlap Weighting A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial
Laine E. Thomas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Efficacy and Safety of Cyclin-Dependent Kinases 4 and 6 Inhibitors in HR+/HER2-Advanced Breast Cancer
Ning Xie et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Addressing Extreme Propensity Scores via the Overlap Weights
Fan Li et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2019)
Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications
Matteo Santoni et al.
BIODRUGS (2019)
OneFlorida Clinical Research Consortium: Linking a Clinical and Translational Science Institute With a Community-Based Distributive Medical Education Model
Elizabeth Shenkman et al.
ACADEMIC MEDICINE (2018)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Saro H. Armenian et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations
Laura M. Spring et al.
ONCOLOGIST (2017)
Introduction to the Analysis of Survival Data in the Presence of Competing Risks
Peter C. Austin et al.
CIRCULATION (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Launching PCORnet, a national patient-centered clinical research network
Rachael L. Fleurence et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2014)
Anthracycline-Induced Cardiomyopathy Clinical Relevance and Response to Pharmacologic Therapy
Daniela Cardinale et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Congestive heart failure in patients treated with doxorubicin - A retrospective analysis of three trials
SM Swain et al.
CANCER (2003)
To cycle or not to cycle: A critical decision in cancer
M Malumbres et al.
NATURE REVIEWS CANCER (2001)
分享论文
